TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Tight Glycaemic Control in Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>=18years~* Acute Myocardial Infarction~* Blood Glucose Level \>=10mmol/L~* Wall motion abnormality on baseline echocardiogram~Exclusion Criteria:~* Active infection/inflammation~* Cardiac shunt~* Cognitive Impairment~* Insulin allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Reflux After Sleeve Using Stretta

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic reflux: (heartburn, chest discomfort, asthma/chronic cough, laryngitis, nocturnal aspiration or regurgitation)~2. On a PPI with GERD-related symptoms~3. On a PPI but like to discontinue them~Exclusion Criteria:~1. Age \<18 or \> 80~2. History of a severe psychiatric disorder: including suicidal ideation, or admission to a psychiatric institution.~3. Unable or unwilling to consent for an invasive procedure.~4. History of intestinal leak after surgery.~5. History of revisional bariatric surgery~6. Significant sleeve abnormalities such and twist or large fundus~7. Hiatal hernia(\>2cm)~8. Pregnancy~9. Inability to comply with study protocols and procedures~10. Esophageal stricture, Eosinophilic Esophagitis or Achalasia~11. Prior esophageal surgery or therapy for Barrett's Esophagus~12. Grades 3 or 4 esophagitis~13. Gastric or esophageal varices~14. History of obstruction of the small bowel or inflammatory bowel disease~15. Pacemaker or implanted cardiac defibrillator~16. Coagulopathy or use of anticoagulants~17. ASA classification \>3~18. Scleroderma or other connective diseases~19. Use of immunosuppressive medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Radiofrequency Energy to the Lower Esophageal Sphincter (LES) (Type: EXPERIMENTAL): All patients that have undergone sleeve gastrectomy as treatment for obesity that have developed severe reflux symptoms will be treated with Stretta (FDA approved device for the management of GERD) and evaluated prospectively for resolution/improvement of reflux symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Complement Inhibition in aHUS Dialysis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years;~* Diagnosis of aHUS with or without identified genetic abnormalities in the complement system or thrombomodulin;~* Stable chronic extracorporeal or peritoneal dialysis therapy since at least 6 months;~* Written informed consent.~Exclusion Criteria:~* Women of childbearing potential or women who are breastfeeding;~* Shiga toxin-associated HUS or secondary forms of thrombotic microangiopathy;~* ADAMTS13 activity \<10 % or circulating anti ADAMTS13 autoantibodies consistent with the diagnosis of thrombotic thrombocytopenic purpura;~* Need for specific intervention with plasma therapy and/or complement inhibitors as deemed clinically appropriate;~* Plasma therapy or treatment with complement inhibitors or antiplatelet and antithrombotic agents over the last two weeks;~* Liver function impairment (serum liver enzymes or bilirubin levels \>3 x upper limit of normal);~* Neutrophil count \< 2000/μL or lymphocyte count \< 1000/μL;~* Infection requiring antibiotic treatment within the previous 4 weeks prior to screening;~* Participated in any clinical study of an investigational product within 30 days prior to screening or within 5 half-lives after taking the last dose;~* History or presence of any medical condition or disease which, in the opinion of the Investigator may place the subject at unacceptable risk for study participation;~* Inability to understand the potential risks and benefits of the study;~* Legal incapacity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CCX168 (Type: EXPERIMENTAL): Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Fosamax in Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Spinal Cord Injury Association (ASIA) A or American Spinal Cord Injury Association (ASIA) B Spinal Cord Injury~Exclusion Criteria:~* History of hypersensitivity to alendronate or other bisphosphonates~* esophageal abnormality~* inability to sit/stand upright for 30 minutes~* creatinine clearance less than 35 milliliters/minute~* hypothyroidism~* malignancy~* pregnancy~* prolonged steroid use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Fosamax (Type: ACTIVE_COMPARATOR): Fosamax at 70 mgs q weekly by mouth for the duration of the study.
- Placebo Sugar Pill (Type: PLACEBO_COMPARATOR): Double blind study using Fosamax versus placebo. Placebo is an inactive drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: External Fixation Versus Splinting of Acute Calcaneus Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntary consent~* Age 18 to 69~* Clinical and/or advanced imaging confirming an acute calcaneal fracture that has occurred within 2 days of which, eventually definitive surgery is recommended/accepted.~* Unable to consent~Exclusion Criteria:~* Age \<18~* Prior surgery of the affected extremity~* Prisoners~* Pregnant women~* Inflammatory arthritis~* Non-English-speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- External fixation (Type: ACTIVE_COMPARATOR): Adults diagnosed with an acute (\<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in external fixator until the patient is deemed clinically appropriate for definitive surgical fixation.
- Splinting (Type: ACTIVE_COMPARATOR): Adults diagnosed with an acute (\<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in a short leg splint until the patient is deemed clinically appropriate for definitive surgical fixation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Radiological diagnosis of hepatic tumor(s) by contrast-enhanced study~* Subjects with advanced HCC who are not eligible for surgical resection or loco-regional therapy.~* Subjects with sorafenib treatment failure due to sorafenib intolerance or radiographic PD (as per RECIST v1.1). Prior sorafenib use should be ≥ 400 mg/day for at least 14 days.~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1~* Child Pugh Score ≤ 6;~* A life expectancy of at least 12 weeks or more~Exclusion Criteria:~* Subjects who have received any systemic target therapy or systemic chemotherapy other than sorafenib for the treatment of HCC.~* Subjects who have received sorafenib within 2 weeks prior to the initiation of the treatment dose, or have any sorafenib-related toxicities not yet resolved to grade 1 or baseline.~* Subjects who have undergone liver transplantation surgery.~* Major surgery within 4 weeks prior to the initiation of the treatment dose (excluding implantation of the intravenous infusion device). Percutaneous liver puncture within 2 weeks prior to the initiation of the treatment dose.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lipotecan (Type: EXPERIMENTAL): Administer 40mg of Lipotecan at D1, D8, D15 of each cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Wellclub Shoulder Therapy Outcome Validation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Shoulder impingement not requiring immediate surgery~Exclusion Criteria:~* Rotator cuff tear (RCT)~* Surgical history of rotator cuff repair (RCR)~* Cortisone injection or other injectable for past 6 months~* Prescription NSAIDs in the past 6 months~* Frozen shoulder syndrome~* Neurological conditions~* Other orthopaedic conditions (spine/neck)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- WellClub Device (Type: EXPERIMENTAL): Hand held device that patients use for home therapy
- Standard Therapy (Type: ACTIVE_COMPARATOR): Standard care therapy for should pain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \<29 6/7 and \>24 0/7 weeks gestational age~* Inborn at the participating institution enrolling the patient~* FIO2 \>25% and Intubated with mean airway pressure \> 5 cm H20~* \<8 hours age at randomization~* Signed informed consent from parent(s)~Exclusion Criteria:~* \<500 g birth weight~* \<24 0/7 weeks gestational age (best estimate)~* Prolonged Premature Rupture of membranes \>3 weeks (21 days)~* Apgar score \< 3 at 5 minutes~* Impending death anticipated within the first 3 days of life, moribund~* Severe congenital anomalies

- Gender: ALL
- Minimum Age: None
- Maximum Age: 8 Hours
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Surfactant (beractant, Survanta initial dose 100 mg/kg and subsequent doses 100 mg/kg phospholipids every 6-12 hours, as needed for up to 4 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
- 2 (Type: EXPERIMENTAL): Surfactant (poractant, Curosurf initial dose 200 mg/kg and subsequent doses 100 mg/kg phospholipids every 12-24 hours as needed for up to 3 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Proven or suspected infection~* Septic shock defined as hypotension requiring vasopressor treatment despite adequate fluid resuscitation~* Informed consent obtained in accordance with local regulations~Exclusion Criteria:~* Not possible to initiate trial drug treatment within 12 hours from onset of vasopressor treatment for septic shock~* Primary cause of hypotension not due to sepsis~* Previous severe sepsis with intensive care unit admission within this hospital stay~* Known/suspected acute mesenteric ischaemia~* Suspicion of concomitant acute coronary syndrome based on clinical symptoms and/or ECG during this episode of septic shock~* Chronic mechanical ventilation for any reason OR severe chronic obstructive pulmonary disease (COPD) requiring either continuous daily oxygen use during the preceding 30 days or mechanical ventilation (for acute exacerbation of COPD) during the preceding 30 days~* Received bone marrow transplant during the preceding 6 months or chemotherapy during the preceding 30 days for lymphoma or leukemia~* Known to be pregnant~* Decision to limit full care taken before obtaining informed consent~* Use of vasopressin in the past 12 hours prior to start of trial drug treatment or use of terlipressin within 7 days prior to start of trial drug treatment~* Prior enrolment in the trial~* Prior use of an investigational medicinal product within the last month OR planned or concurrent participation in a clinical trial for any investigational drug or investigational device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Selepressin 1 (Type: EXPERIMENTAL): Starting dose 1.7 ng/kg/min
- Selepressin 2 (Type: EXPERIMENTAL): Starting dose 2.5 ng/kg/min
- Selepressin 3 (Type: EXPERIMENTAL): Starting dose 3.5 ng/kg/min
- Selepressin 4 (Type: EXPERIMENTAL): Starting dose 5.0 ng/kg/min~The highest dosing regimen of selepressin was not investigated in the trial as the desired primary outcome for selepressin 3 arm was not achieved, and the trial was terminated for futility.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Time To Complications Occurs in Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetes type 1, 2 or LADA: 18-75 years of age.~* Group A: 150 Type 1 Diabetes, duration 15 years (+/-2 years) and 150 Type 2~* Diabetes 2 years (+/-2 years) (50% F/M)~* Group B: 150 Type 1 Diabetes, duration 20 years (+/-2 years) and 150 Type 2~* Diabetes 7 years (+/-2 years) (50% F/M)~* Group C: 150 Type 1 Diabetes, duration 25 years (+/-2 years) and 150 Type 2~* Diabetes 12 years (+/-2 years) (50% F/M)~* Group D: 50 LADA, onset after 35 years of age, duration of 5-10 years (50% F/M)~* Type 1 Diabetes: Positive ICA antibodies and/or GAD-antibodies and/or neg C-peptide. Debut \<30 years of age.~* Type 2 Diabetes: Negative ICA-antibodies and GAD-antibodies and pos C-peptide (\>0.35 mmol/l).~* LADA: Positive ICA-antibodies and/or GAD-antibodies. Debut \>35 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: None): 150 Type 1 Diabetes, duration of 15 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 2 years (+/- 2 years) (50% women / men)
- Group B (Type: None): 150 Type 1 Diabetes, duration of 20 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 7 years (+/- 2 years) (50% women / men)
- Group C (Type: None): 150 Type 1 Diabetes, duration of 25 years (+/- 2 years) and 150 Type 2 Diabetes duration of 12 years (+/- 2 years) (50% women / men)
- Group D (Type: None): 50 LADA (Late Autoimmune Diabetes in Adults), debut after 35 years of age, duration of 5-10 years (50% women / men)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy women, ASA class 1 (normal healthy) or class 2 (with mild systemic disease);~* undergoing IVF or ICSI and reaching the stage of egg collection;~* with ultrasonically diagnosed hydrosalpinx and identifiable during the phase of ovarian stimulation;~* giving written informed consent.~Exclusion Criteria:~* patients not giving written informed consent;~* patients cancelled for poor ovarian response;~* ultrasonically diagnosed hydrosalpinx and identifiable for the first time at egg-collection

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): For those assigned to Group 1, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
- 2 (Type: NO_INTERVENTION): Patients assigned to group 2 will not have the hydrosalpinx aspirated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-small-cell carcinoma of the lung~* Patients with locally advanced disease or metastatic disease, candidates to surgery after evaluation by oncologist and thoracic surgeon~* Tumour with possibility of curative surgery~* At least one uni-dimensionally measurable lesion~* Adequate pulmonary function to perform the planned surgical resection~Exclusion Criteria:~* Active infection (at the investigator's discretion)~* Pregnancy or breast-feeding~* Serious concomitant illness at the investigator's discretion~* Previous diagnosis of malignant disease~* They have received treatment during the last 30 days with a drug, other than the study drug, that has not received regulatory approval for any indication at the time of their entry in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Tolerability and Acceptability of a New Plant-based Formula for Young Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male and female children as per the clinical judgement of the Investigator~2. Singleton children~3. Children ≥12 and \<36 months of age at screening~4. Children who have been drinking dairy based beverages or plant-based milk replacements (in combination with breastfeeding or not) for at least 3 weeks prior to screening~5. Children are familiar with drinking ≥400 ml/day of dairy based beverages or plant-based milk replacements,~6. Written informed consent from the parent(s) and/or legal guardian(s) (≥ 18 years of age)~Exclusion Criteria:~1. Children with medical conditions requiring a special diet such as fibre-free diet, food allergy, or food intolerances~2. Children with current or previous illnesses/conditions or interventions which could interfere with the study or its outcome parameters (e.g. diarrhoea requiring treatment, constipation requiring treatment, regurgitation requiring treatment, dental/medical procedures which may impact oral feeding), as per the clinical judgment of the Investigator, within 3 weeks prior to screening~3. Use of medication or nutritional/food supplements known to impact GI tolerance (e.g. anti-regurgitation (including any thickening agent), anti-reflux, anti-diarrheal, laxative medication, systemic antibiotic, probiotic supplements) within 3 weeks prior to screening~4. Children who are using diapers~5. Siblings of participating children~6. Participation in any other study involving investigational or marketed products concomitantly or within 3 weeks prior to screening~7. Children of employees and/or family members or relatives of employees of Danone Nutricia Indonesia or of the participating research institute and local community facilities~8. Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol instructions, including daily completion of the diaries by the parents.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 3 Years
- Healthy Volunteers: t

Study Arms:
- Plant based formula for young children (Type: OTHER): The study is designed with a single arm, so all subjects will receive the study product.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues